Table 44. Patient characteristics–perphenazine versus aripiprazole

| **Author, Year** | **Study Characteristics** | **Inclusion and Exclusion Criteria** | **Population** | **Interventions** |
| --- | --- | --- | --- | --- |
| **Kane et al. 2007**93 | ***Study design:*** RCT  ***Registration #:*** NR  ***Study population:*** Schizophrenia  ***DSM Classification:*** DSM IV  ***Study period:*** Aug 2000 to Mar 2001  ***Number of centers:*** Multicenter(n = 59)  ***Setting:*** Outpatient  ***Country:*** USA, Canada  ***Financial support:*** Industry (Bristol–Myers Squibb)    ***Washout period performed:*** yes (2–14d)  ***Run-in phase performed:*** yes (4–6 wks)  ***Followup period:*** 6 wks | ***Main inclusion criteria:*** > 18 yrs. Sz; Tx resistant with Olanzapine, Risperidone; PANSS≥75. CGI–S≥4; At least 2 of: conceptual disorganization, suspiciousness, hallucinatory behavior, delusions. Tx as outpatient for one 3 month period in last 2 yrs.  ***Main exclusion criteria:*** Dx of schizoaffective disorder; residual Sz; bipolar disorder; presentation or Hx consistent with delirium; dementia; amnesia or other cognitive disorders; refractory response to prior clozapine or perphenazine; likely to require prohibited concomitant therapy; current or recent psychoactive drug or alcohol abuse or dependence; Hx of suicidal attempts or thoughts; known allergy to study drugs; Tx with an investigational drug within 4 wk of washout phase; previous enrollment in an aripiprazole clinical study; had other acute or unstable medical condition; pregnant or lactating | ***G1:***  ***Age (mean±SD):*** 41.60±10.87  ***Males (n(%)):*** 94/146 (64.4%)  ***Ethnicity:*** Caucasian 75/146 (51.4%)  ***BL symptom scores:*** BPRS (mean±SD): 17.6±3.34  PANSS (mean±SD): 99.5±15.61  ***G2:***  ***Age (mean±SD):*** 42.60±12.40  ***Males (n(%)):*** 114/154 (74%)  ***Ethnicity:*** Caucasian 76/154 (49.4%)  ***BL symptom scores:*** BPRS (mean±SD):  17.2±2.86  PANSS (mean±SD): 97.5±15.62 | ***G1:***  ***Classification:*** FGA  ***Drug:*** Perphenazine  ***Dosage:*** 8–64mg/d  ***Intervals:*** BID if > 8mg/d    ***G2:***  ***Classification:*** SGA  ***Drug:*** Aripiprazole  ***Dosage:*** 15–30mg/d  ***Intervals:*** NR |

AP = antipsychotic; BID  = Twice daily; BL = baseline; BPRS = Brief Psychiatric Rating Scale; CGI = Clinical Global Impressions; d = day; DSM = Diagnostic and Statistical Manual of Mental Disorders; DX = diagnosis; FGA = first-generation antipsychotic; Hx = history; mg = milligram; n = number; NA = not applicable; NR = not reported; PANSS  = Positive and Negative Syndrome Scale; RCT = randomized controlled trial; SD = standard deviation; SGA = second-generation antipsychotic; Sz = schizophrenia; Tx = treatment; wk = week; yr = year